Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Looking for instant savings? Check out these effective ways to save money instantly and improve your financial situation.
11,272 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Microsoft’s Satya Nadella signals a data-centric AI strategy, arguing buyers must reveal proprietary know-how to unlo...
Sirius XM stunned investors with a near-50% rise in the first half of 2026. This analysis breaks down the catalysts, ...
Compass has filed ethics complaints against Zillow across 26 states, highlighting disputes over how active listings a...
With a 0.15% expense ratio, QQQM offers a cheaper path to Nasdaq-100 exposure. The potential cost savings could meani...
Three social platforms are drawing fresh attention as growth meets reasonable prices. Here’s a practical, investor-fr...
Investors chasing SpaceX-style wins without a private bet must weigh public players carefully. This guide compares AS...
A new paid service promises ultra-fast access to high-profile Truth Social posts, including those from President Trum...
ARKK and ARKG are back in the biotech spotlight as Cathie Wood makes new bets after a setback in a key antisense stoc...
Apple sits near a record price, but its future may still be bright. This guide breaks down the numbers, the moat, and...
Gas prices have climbed back above the $4 per gallon mark, driven by geopolitical tensions and supply concerns. This ...
Two pharmaceutical giants are in court over GLP-1 advertising. This tangle could redefine how GLP-1s are marketed and...